Dear Colleagues,

I am exhilarated to meet you all through this August 2014 edition of Oviya MedSafe’s newsletter and share with you the news of the milestones we have attained of late, as well as indicate some of our plans for the future. 

To start with, my recent visit to Europe has made me realise that, as a brand, Oviya MedSafe already has a global reach, which has now been augmented and formalised, with the incorporation of our wholly owned UK subsidiary Oviya MedSafe UK Ltd in July 2014. In subsequence, we intend to grow and position our UK entity not only as the hub for our European expansion plans but also as the orthocentre of all our future international businesses, with our Indian parent company Oviya MedSafe Pvt Ltd retaining charge of our Indian operations.

Thanks to leading UK-based global pharmaceutical industry magazine Pharmaphorum, which on 12-Aug-2014 published my article Incretin-based anti-diabetic therapies: a pharmacovigilance perspective, I have been able to bridge my medical specialty of Diabetology and my chosen profession of Pharmacovigilance, on an international platform for the first time. It is my pleasure to acknowledge the contributions of my Oviya MedSafe colleagues Gayathri, Kabila and Ganesan to this article. We, as Team Oviya MedSafe, request you to read the article by clicking on its title mentioned above and look forward to your feedback in reply.

In April 2014, we announced Oviya MedSafe’s partnership with UK-based software company Assured Information Systems to use and promote the use of their hosted pharmacovigilance software database PV247 in India and the overall Asia Pacific region. This alliance has been forged to pass on to the end client its benefit of cost-effectiveness without compromise on the need for a comprehensive solution. Meeting drug safety regulatory obligations often means that a pharmaceutical company must heavily invest upfront in setting up a pharmacovigilance department and system in their organisations. Our partnership enables such companies, especially generic drugmakers of any size and small & medium-sized innovators, to achieve a solution with a minimal budget and very less time.

Ever since the collaboration with Assured was published, we have been receiving several inquiries about the capability and functionality of the PV247 hosted pharmacovigilance software database. To share this know-how with one and all, Oviya MedSafe, along with Assured, will facilitate a free one hour webinar session titled Assuring Cost Effective Global Pharmacovigilance Compliance.  This webinar would include a free demonstration and has been tailored for pharmaceutical companies globally.  Please confirm your interest in registering for this free webinar by contacting us with your name, designation, e-mail address and the name of your organisation. You will receive the confirmation of your registration and call-in details for the webinar subsequently. If you are unable to attend this webinar or would like more information on PV247, please visit www.pv247.com

Before I conclude, I also want to let you know that if anyone of you is interested to know more about Oviya MedSafe’s capabilities and track record in pharmacovigilance, you are welcome to contact us to fix an exclusive webinar, during which I will personally walk you through the various services we offer in drug safety.

Looking forward to meeting you all in September 2014 with more exciting news,
 
With thanks & regards, 
Dr J Vijay Venkatraman 
MBBS, F. Diab., MBA 

Managing Director & CEO, 
Oviya MedSafe 
Pharmacovigilance Consulting & Drug Safety Services
Coimbatore, India & London, UK

India Office: +91-422-2444442
UK Office:    +44-8452-733839 

Website: www.oviyamedsafe.com 
Facebook: www.facebook.com/OviyaMedSafe 
Twitter: www.twitter.com/OviyaMedSafe 
LinkedIn: www.linkedin.com/company/oviya-medsafe